Biotech Values

[oldberkeley]

Blade & Dew- I agree with your thesis, makes a lot of sense. Neither Teva nor Momenta/Novartis has any shortage of good attorneys and I can't believe that MNTA's guys are advising the company that this suit is a potential winner.

My only question arises from that point. It seems a bit of a risky gambit. If this suit is a business strategy to show the market that MNTA can also play offense, don't you feel that either a dismissal or worse yet an outright loss will weaken the market perception of MNTA—as an astute group of businessmen, something the street needs to believe—and by association the science and the product itself?

Not to mention the PPS.